Novartis BexseroŽ vaccine approved by FDA for the prevention of meningitis B
Novartis announced the FDA has granted accelerated approval of BexseroŽ (Meningococcal Group B Vaccine [recombinant, adsorbed]) for active immunization to prevent invasive meningococcal disease caused by serogroup B in adolescents and young adults from 10 years through 25 years of age. January 23, 2015